Individual Trade-Offs Between Possible Benefits and Risks of Cancer Treatments: Results from a Stated Preference Study with Patients with Multiple Myeloma.
Postmus D et al. Oncologist. 2017 Oct 27. pii: theoncologist.2017-0257. doi: 10.1634/theoncologist.2017-0257. [Epub ahead of print].
Immunoparesis and polyclonal immunoglobulin recovery after auto-SCT for patients with multiple myeloma treated at a single institution.
Jimenez-Zepeda VH et al. Leuk Lymphoma. 2017 Nov 21:1-7. doi: 10.1080/10428194.2017.1403026. [Epub ahead of print].
Model-Based Meta-Analysis for Multiple Myeloma: A Quantitative Drug-Independent Framework for Efficient Decisions in Oncology Drug Development.
Teng Z et al. Clin Transl Sci. 2017 Nov 23. doi: 10.1111/cts.12524. [Epub ahead of print].
Frailty and the management of hematologic malignancies.
Abel GA et al. Blood. 2017 Nov 15. pii: blood-2017-09-746420. doi: 10.1182/blood-2017-09-746420. [Epub ahead of print].
Cognitive dysfunction among newly diagnosed older patients with hematological malignancy: frequency, clinical indicators and predictors.
Aiki S et al. Jpn J Clin Oncol. 2017 Nov 10:1-7. doi: 10.1093/jjco/hyx159. [Epub ahead of print].
CD38 antibodies in multiple myeloma: back to the future.
van de Donk NWCJ et al. Blood. 2017 Nov 8. pii: blood-2017-06-740944. doi: 10.1182/blood-2017-06-740944. [Epub ahead of print].
Redirecting T cells to hematological malignancies with bispecific antibodies.
Velasquez MP et al. Blood. 2017 Nov 8. pii: blood-2017-06-741058. doi: 10.1182/blood-2017-06-741058. [Epub ahead of print].
Fatigue- and health-related quality-of-life in anemic patients with lymphoma or multiple myeloma.
Gascón P et al. Support Care Cancer. 2017 Nov 7. doi: 10.1007/s00520-017-3948-5. [Epub ahead of print].
Detection of three blood donors with multiple myeloma by routine viral individual-donor nucleic acid testing screening.
Babic I et al. Transfusion. 2017 Nov;57(11):2813-2814. doi: 10.1111/trf.14319.
Racial disparity in utilization of therapeutic modalities among multiple myeloma patients: a SEER-medicare analysis.
Ailawadhi S et al. Cancer Med. 2017 Nov 3. doi: 10.1002/cam4.1246. [Epub ahead of print].
Cardio-oncology in multiple myeloma: is it time for a specific focus?
Mancuso S et al. Leuk Lymphoma. 2017 Oct 31:1-3. doi: 10.1080/10428194.2017.1393674. [Epub ahead of print].
Stem cell mobilization in poor mobilizers with multiple myeloma or lymphoma before and after introduction of plerixafor: a single-center comparative analysis using a cost-efficient single fixed-dose schedule.
Greil C et al. Leuk Lymphoma. 2017 Oct 30:1-4. doi: 10.1080/10428194.2017.1393673. [Epub ahead of print].
The Proteasome and Myeloma-Associated Bone Disease.
Accardi F et al. Calcif Tissue Int. 2017 Oct 28. doi: 10.1007/s00223-017-0349-1. [Epub ahead of print].
Response comparison of multiple myeloma and monoclonal gammopathy of undetermined significance to the same anti-myeloma therapy: a retrospective cohort study.
Campbell JP et al. Lancet Haematol. 2017 Nov 13. pii: S2352-3026(17)30209-0. doi: 10.1016/S2352-3026(17)30209-0. [Epub ahead of print].
CAR T cell therapy for multiple myeloma: where are we now and where are we headed?
Ghosh A et al. Leuk Lymphoma. 2017 Nov 6:1-12. doi: 10.1080/10428194.2017.1393668. [Epub ahead of print].